Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-29T00:00:38.745Z Has data issue: false hasContentIssue false

10 - Hypersalivation

Published online by Cambridge University Press:  02 December 2009

M. Fiorella Contarino
Affiliation:
Academic Medical Centre, Amsterdam, The Netherlands
Alberto Albanese
Affiliation:
Istituto Nazionale Neurologico Carlo Besta, Università Cattolica del Sacro Cuore, Milano, Italy
Anthony B. Ward
Affiliation:
University Hospital of North Staffordshire
Michael P. Barnes
Affiliation:
Hunters Moor Regional Neurological Rehabilitation Centre
Get access

Summary

Introduction

The terms drooling, hypersalivation and sialorrhoea have been used interchangeably in scientific jargon. Drooling and sialorrhoea can be considered as synonymous, both indicating ‘unintentional loss of saliva from the mouth’, perhaps being more profuse in drooling. They usually refer to difficulty in swallowing, either because of pharyngeal muscle weakness, or of reduced spontaneous swallowing or incoordination, leading to excessive pooling of saliva in the anterior mouth and consequent spillage. Hypersalivation (or absolute hypersalivation) is an ‘abnormally increased production of saliva’, and does not necessarily lead to drooling, if swallowing is efficient. Drooling is sometimes simply referred to as ‘relative hypersalivation’.

Background and clinical description

Saliva performs a number of functions: it facilitates swallowing, keeps the mouth moist and teeth clean, conveys molecules to stimulate the taste, and has digestive and antibacterial functions. Normal daily salivary production is about 1–2 l (0.5–1.5 ml / min). The majority of daily salivary production is secreted by the parotid and submandibular glands; the parotids account for about 20 per cent of all saliva production, whilst the submandibular glands produce about 70 per cent (Table 10.1). Sympathetic impulses modulate the output of preformed components, including amylase and lysozyme, from salivary cells.

The swallowing reflex normally prevents drooling. Swallowing is a complex task requiring intact neuromuscular coordination: the mean number of swallowing actions per hour is 25.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wolff, A., Harell, D., Gadoth, N. and Mass, E. (2002). Submandibular and sublingual salivary gland function in familial dysautonomia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 94(3), 315–19.CrossRefGoogle ScholarPubMed
Johnson, H., King, J. and Reddihough, D. S. (2001). Children with sialorrhoea in the absence of neurological abnormalities. Child Care Health Dev., 27(6), 591–602.CrossRefGoogle ScholarPubMed
Giess, R., Naumann, M., Werner, E., Riemann, R., Beck, M., Puls, I., Reiners, C. and Toyka, K. V. (2000). Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry, 69(1), 121–3.CrossRefGoogle ScholarPubMed
Glickman, S. and Deaney, C. N. (2001). Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report. Eur. J. Neurol., 8(6), 567–71.CrossRefGoogle ScholarPubMed
Harriman, M., Morrison, M., Hay, J., Revonta, M., Eisen, A. and Lentle, B. (2001). Use of radiotherapy for control of sialorrhoea in patients with amyotrophic lateral sclerosis. J. Otolaryngol., 30(4), 242–5.CrossRefGoogle ScholarPubMed
Pal, P. K., Calne, D. B., Calne, S. and Tsui, J. K. (2000). Botulinum toxin A as treatment for drooling saliva in PD. Neurology, 54(1), 244–7.CrossRefGoogle ScholarPubMed
Hyson, H. C., Johnson, A. M. and Jog, M. S. (2002). Sublingual atropine for sialorrhoea secondary to parkinsonism: a pilot study. Mov. Disord., 17(6), 1318–20.CrossRefGoogle ScholarPubMed
Koike, Y. and Takahashi, A. (1997). Autonomic dysfunction in Parkinson's disease. Eur. Neurol., 38(Suppl. 2), 8–12.CrossRefGoogle ScholarPubMed
Tahmassebi, J. F. and Curzon, M. E. (2003). Prevalence of drooling in children with cerebral palsy attending special schools. Dev. Med. Child Neurol., 45(9), 613–17.CrossRefGoogle ScholarPubMed
Tahmassebi, J. F. and Curzon, M. E. (2003). The cause of drooling in children with cerebral palsy: hypersalivation or swallowing defect?Int. J. Paediatr. Dent., 13(2), 106–11.CrossRefGoogle ScholarPubMed
Restivo, D. A., Lanza, S., Patti, F., Giuffrida, S., Marchese-Ragona, R., Bramanti, P. and Palmeri, A. (2002). Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology, 59(12), 1971–3.CrossRefGoogle ScholarPubMed
Suskind, D. L. and Tilton, A. (2002). Clinical study of botulinum-A toxin in the treatment of sialorrhoea in children with cerebral palsy. Laryngoscope, 112(1), 73–81.CrossRefGoogle ScholarPubMed
Neverlien, P. O., Sorumshagen, L., Eriksen, T., Grinna, T., Kvalshaugen, H. and Lind, A. B. (2000). Glycopyrrolate treatment of drooling in an adult male patient with cerebral palsy. Clin. Exp. Pharmacol. Physiol., 27(4), 320–2.CrossRefGoogle Scholar
Blasco, P. A. and Stansbury, J. C. (1996). Glycopyrrolate treatment of chronic drooling. Arch. Pediatr. Adolesc. Med., 150(9), 932–5.CrossRefGoogle ScholarPubMed
Olsen, A. K. and Sjogren, P. (1999). Oral glycopyrrolate alleviates drooling in a patient with tongue cancer. J. Pain. Symptom. Manage., 18(4), 300–2.CrossRefGoogle Scholar
Mier, R. J., Bachrach, S. J., Lakin, R. C., Barker, T., Childs, J. and Moran, M. (2000). Treatment of sialorrhoea with glycopyrrolate: a double-blind, dose-ranging study. Arch. Pediatr. Adolesc. Med., 154(12), 1214–18.CrossRefGoogle ScholarPubMed
Kim, W. O., Kil, H. K., Yoon, D. M. and Cho, M. J. (2003). Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate. Yonsei Med. J., 44(4), 579–82.CrossRefGoogle ScholarPubMed
Zeppetella, G. (1999). Nebulized scopolamine in the management of oral dribbling: three case reports. J. Pain Symptom. Manage., 17(4), 293–5.CrossRefGoogle ScholarPubMed
Comley, C., Galletly, C. and Ash, D. (2000). Use of atropine eye drops for clozapine induced hypersalivation. Aust. N. Z. J. Psychiatry, 34(6), 1033–4.CrossRefGoogle ScholarPubMed
Crysdale, W. S., Raveh, E., McCann, C., Roske, L. and Kotler, A. (2001). Management of drooling in individuals with neurodisability: a surgical experience. Dev. Med. Child. Neurol., 43(6), 379–83.CrossRefGoogle ScholarPubMed
Mankarious, L. A., Bottrill, I. D., Huchzermeyer, P. M. and Bailey, C. M. (1999). Long-term follow-up of submandibular duct rerouting for the treatment of sialorrhoea in the pediatric population. Otolaryngol. Head Neck Surg., 120(3), 303–7.CrossRefGoogle ScholarPubMed
Stern, Y., Feinmesser, R., Collins, M., Shott, S. R. and Cotton, R. T. (2002). Bilateral submandibular gland excision with parotid duct ligation for treatment of sialorrhoea in children: long-term results. Arch. Otolaryngol. Head Neck Surg., 128(7), 801–3.CrossRefGoogle ScholarPubMed
Panarese, A., Ghosh, S., Hodgson, D., McEwan, J. and Bull, P. D. (2001). Outcomes of submandibular duct re-implantation for sialorrhoea. Clin. Otolaryngol., 26(2), 143–6.CrossRefGoogle ScholarPubMed
Wilson, S. W. and Henderson, H. P. (1999). The surgical treatment of drooling in Leicester: 12 years experience. Br. J. Plast. Surg., 52(5), 335–8.CrossRefGoogle ScholarPubMed
Uppal, H. S., De, R., D'Souza, A. R., Pearman, K. and Proops, D. W. (2003). Bilateral submandibular duct relocation for drooling: an evaluation of results for the Birmingham Children's Hospital. Eur. Arch. Otorhinolaryngol., 260(1), 48–51.Google ScholarPubMed
Ozgenel, G. Y. and Ozcan, M. (2002). Bilateral parotid-duct diversion using autologous vein grafts for the management of chronic drooling in cerebral palsy. Br. J. Plast. Surg., 55(6), 490–3.CrossRefGoogle ScholarPubMed
Klem, C. and Mair, E. A. (1999). Four-duct ligation: a simple and effective treatment for chronic aspiration from sialorrhoea. Arch. Otolaryngol. Head Neck Surg., 125(7), 796–800.Google Scholar
Shirley, W. P., Hill, J. S., Woolley, A. L. and Wiatrak, B. J. (2003). Success and complications of four-duct ligation for sialorrhoea. Int. J. Pediatr. Otorhinolaryngol., 67(1), 1–6. Review.CrossRefGoogle Scholar
Borg, M. and Hirst, F. (1998). The role of radiation treatment in the management of sialorrhoea. Int. J. Radiat. Oncol. Biol. Phys., 41, 1113–19.CrossRefGoogle Scholar
Johnson, H. M., Reid, S. M., Hazard, C. J., Lucas, J. O., Desai, M. and Reddihough, D. S. (2004). Effectiveness of the Innsbruck Sensorimotor Activator and Regulator in improving saliva control in children with cerebral palsy. Dev. Med. Child. Neurol., 46(1), 39–45.CrossRefGoogle ScholarPubMed
Lloyd Faulconbridge, R. V., Tranter, R. M., Moffat, V. and Green, E. (2001). Review of management of drooling problems in neurologically impaired children: a review of methods and results over 6 years at Chailey Heritage Clinical Services. Clin. Otolaryngol., 26(2), 76–81.CrossRefGoogle ScholarPubMed
Wong, V., Sun, J. G. and Wong, W. (2001). Traditional Chinese medicine (tongue acupuncture) in children with drooling problems. Pediatr. Neurol., 25(1), 47–54.CrossRefGoogle ScholarPubMed
Erbguth, F. J. (1998). Botulinum toxin, a historical note. Lancet, 351, 1820.CrossRefGoogle ScholarPubMed
Bushara, K. O. (1997). Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment – botulinum toxin A injections of the parotid glands. Med. Hypotheses, 48(4), 337–9.CrossRefGoogle ScholarPubMed
Ellies, M., Laskawi, R., Tormahlen, G. and Gotz, W. (2000). The effect of local injection of botulinum toxin A on the parotid gland of the rat: an immunohistochemical and morphometric study. J. Oral. Maxillofac. Surg., 58(11), 1251–6.CrossRefGoogle ScholarPubMed
Shaari, C. M., Wu, B., Biller, H. F., Chuang, S. and Sanders, I. (1998). Botulinum toxin decreases salivation from canine submandibular glands. Otolaryngol. Head Neck Surg., 118, 452–7.Google ScholarPubMed
Brashear, A., Lew, M. F., Dykstra, D. D., Comella, C. L., Factor, S. A., Rodnitzky, R. L., Trosch, R., Singer, C., Brin, M. F., Murray, J. J., Wallace, J. D., Willmer-Hulme, A. and Koller, M. (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology, 53(7), 1439–46.CrossRefGoogle ScholarPubMed
Brin, M. F., Lew, M. F., Adler, C. H., Comella, C. L., Factor, S. A., Jankovic, J., O'Brien, C., Murray, J. J., Wallace, J. D., Willmer-Hulme, A. and Koller, M. (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology, 53(7), 1431–8.CrossRefGoogle Scholar
Dressler, D., Adib Saberi, F. and Benecke, R. (2002). Botulinum toxin type B for treatment of axillar hyperhidrosis. J. Neurol., 249(12), 1729–32.CrossRefGoogle ScholarPubMed
Racette, B. A., Lopate, G., Good, L., Sagitto, S. and Perlmutter, J. S. (2002). Ptosis as a remote effect of therapeutic botulinum toxin B injection. Neurology, 59(9), 1445–7.CrossRefGoogle ScholarPubMed
Dressler, D. and Benecke, R. (2003). Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur. Neurol., 49(1), 34–8.CrossRefGoogle ScholarPubMed
Birklein, F., Eisenbarth, G., Erbguth, F. and Winterholler, M. (2003). Botulinum toxin type B blocks sudomotor function effectively: a 6 month follow up. J. Invest. Dermatol., 121(6), 1312–16.CrossRefGoogle ScholarPubMed
Ondo, W. G., Hunter, C. and Moore, W. (2004). A double-blind placebo-controlled trial of botulinum toxin B for sialorrhoea in Parkinson's disease. Neurology, 62(1), 37–40.CrossRefGoogle ScholarPubMed
Ellies, M., Laskawi, R., Rohrbach-Volland, S. and Arglebe, C. (2003). Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J. Oral. Maxillofac. Surg., 61(4), 454–7.CrossRefGoogle ScholarPubMed
Mancini, F., Zangaglia, R., Cristina, S., Sommaruga, M. G., Martignoni, E., Nappi, G. and Pacchetti, C. (2003). Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov. Disord., 18(6), 685–8.CrossRefGoogle ScholarPubMed
Naumann, M., Hofmann, U., Bergmann, I., Hamm, H., Toyka, K. V. and Reiners, K. (1998). Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch. Dermatol., 134, 301–4.CrossRefGoogle ScholarPubMed
Porta, M., Gamba, M., Bertacchi, G. and Vaj, P. (2001). Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J. Neurol. Neurosurg. Psychiatry, 70(4), 538–40.CrossRefGoogle ScholarPubMed
Racette, B. A., Good, L., Sagitto, S. and Perlmutter, J. S. (2003). Botulinum toxin B reduces sialorrhoea in parkinsonism. Mov. Disord., 18(9), 1059–61.CrossRefGoogle ScholarPubMed
Kahl, K. G., Hagenah, J., Zapf, S., Trillenberg, P., Klein, C. and Lencer, R. (2004). Botulinum toxin as an effective treatment of clozapine-induced hypersalivation. Psychopharmacology (Berl.).CrossRefGoogle ScholarPubMed
Naumann, M., Zellner, M., Toyka, K. V. and Reiners, K. (1997). Treatment of gustatory sweating with botulinum toxin. Ann. Neurol., 42, 973–5.Google ScholarPubMed
Teive, H. A., Troiano, A. R., Robert, F., Iwamoto, F. M., Maniglia, J. J., Mocellin, M. and Werneck, L. C. (2003). Botulinum toxin for treatment of Frey's syndrome: report of two cases. Arq. Neuropsiquiatr., 61(2A), 256–8.CrossRefGoogle ScholarPubMed
Lipp, A., Trottenberg, T., Schink, T., Kupsch, A. and Arnold, G. (2003). A randomized trial of botulinum toxin A for treatment of drooling. Neurology, 61(9), 1279–81.CrossRefGoogle ScholarPubMed
Winterholler, M. G., Erbguth, F. J., Wolf, S. and Kat, S. (2001). Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of transductal approach. J. Neurol. Neurosurg. Psychiatry, 70, 417–18.CrossRefGoogle ScholarPubMed
Bhatia, K. P., Munchau, A. and Brown, P. (1999). Botulinum toxin is a useful treatment in excessive drooling in saliva. J. Neurol. Neurosurg. Psychiatry, 67(5), 697.CrossRefGoogle ScholarPubMed
Jost, W. H. (1999). Treatment of drooling in Parkinson's disease with botulinum toxin. Mov. Disord., 14(6), 1057.3.0.CO;2-4>CrossRefGoogle ScholarPubMed
Bothwell, J. E., Clarke, K., Dooley, J. M., Gordon, K. E., Anderson, R., Wood, E. P., Camfield, C. S. and Camfield, P. R. (2002). Botulinum toxin A as a treatment for excessive drooling in children. Pediatr. Neurol., 27(1), 18–22.CrossRefGoogle ScholarPubMed
Jongerius, P. H., Rotteveel, J. J., Hoogen, F., Joosten, F., Hulst, K. and Gabreels, F. J. (2001). Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur. J. Pediatr., 160(8), 509–12.CrossRefGoogle ScholarPubMed
Friedman, A. and Potulska, A. (2001). Quantitative assessment of parkinsonian sialorrhoea and results of treatment with botulinum toxin. Parkinsonism Relat. Disord., 7(4), 329–32.CrossRefGoogle ScholarPubMed
Contarino, M. F., Pompili, M., Tittoto, P., Vanacore, N., Sabatelli, M., Cedrone, A., Rapaccini, G. L., Gasbarrini, G., Tonali, P. A., Bentivoglio, A. R. (2006). Botulinum toxin B ultrasound-guided injections for sialorrhea in Amyotrophic Lateral sclerosis and Parkinson's disease. Parkinsonism Relat. Disord. [Epub ahead of print]Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×